There is great news for cancer patients and healthcare professionals across India. A leading Indian pharmaceutical company named Shilpa Medicare Limited has achieved a major milestone in medicine. The company has received final approval from government experts to launch a new type of injection that helps control severe nausea and vomiting caused by cancer treatments. This new medicine will make cancer treatment much easier and more comfortable for patients.
What is the Big Announcement from Shilpa Medicare?
Government Approval Granted
Shilpa Medicare announced that the Subject Expert Committee (SEC) under India's central drug control authority, known as CDSCO, has approved their new medicine named OERIS. This approval allows the company to sell and market the injection across the nation.
A First-of-Its-Kind Medicine in the World
This newly approved injection, OERIS (Ondansetron Extended-Release Injection, 100 mg/mL), is the world's very first long-acting injection of its kind. While normal injections only work for a few hours, just one single injection of OERIS works continuously inside the body for up to 5 days (120 hours).
Why is Nausea and Vomiting a Big Problem in Cancer Treatment?
Side Effects of Chemotherapy
Cancer patients often receive a treatment called chemotherapy to destroy cancer cells. However, chemotherapy chemicals cause very painful side effects, including heavy nausea and constant vomiting. This makes patients feel extremely weak, dehydrated, and uncomfortable during their treatment cycle.
The Difficulty with Regular Medicines
Normally, doctors have to give patients multiple daily tablets or regular injections to prevent this vomiting. Patients often struggle to swallow tablets when they feel nauseous, and repeated needle pricks cause additional pain and stress.
How OERIS Solves This Problem for Patients
One Single Injection for Five Days
With OERIS, patients will not need repeated daily injections or pills. A single dose gives continuous protection against vomiting for a full five days. This brings massive relief to cancer patients who are already fighting a tough disease.
Major Benefits for Patients and Doctors
This new medicine offers several major advantages for everyone involved in cancer care:
- Less Pain and Stress: Patients do not have to endure repeated daily injections during chemotherapy sessions.
- Better Convenience: One single shot covers the most critical 5-day period after chemotherapy.
- Time Saved for Hospital Staff: Nurses and doctors do not need to give repeated medicines constantly, saving valuable medical time.
- Safe and Effective: The medicine went through detailed testing in multiple health centers to prove it is both safe and effective.
Strong Patent Protection
Shilpa Medicare has secured patent protection for this unique medicine formula in India until the year 2039. This means no other company can copy this specific long-acting formula for many years to come.
What Management Says and What Happens Next?
Official Launch in India
After getting the final marketing paperwork from the drug authority, Shilpa Medicare plans to launch OERIS across hospitals and cancer centers in India soon.
Company Vision for Patient Care
Mr. Vishnukant Bhutada, the Managing Director of Shilpa Medicare Limited, expressed great pride in this achievement. He stated that getting final approval for OERIS is a key moment in their goal to improve cancer patient support. He emphasized that the company remains dedicated to making innovative, patient-first medicines that solve real medical problems and make treatments gentler.
Conclusion
A Bright Future for Cancer Support Care
Medical advancements like OERIS show how Indian pharmaceutical research is helping solve complex global health challenges. By turning a daily struggle into a single five-day dose, Shilpa Medicare is helping cancer patients complete their treatment with greater ease, comfort, and dignity.